C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

Summary Background Associations of C-reactive protein (CRP) concentration with risk of major diseases can best be assessed by long-term prospective follow-up of large numbers of people. We assessed the associations of CRP concentration with risk of vascular and non-vascular outcomes under different...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) 2010, Vol.375 (9709), p.132-140
Main Authors:	Kaptoge, Stephen, Di Angelantonio, Emanuele, Lowe, Gordon, Pepys, Mark B, Thompson, Simon G, Collins, Rory, Danesh, John
Format:	Article
Language:	eng
Subjects:	Alcohol Drinking - blood Alcohol Drinking - epidemiology Biological and medical sciences Biomarkers - blood Blood Pressure Body Mass Index C-Reactive Protein - analysis Cardiology. Vascular system Cardiovascular disease Cholesterol - blood Coronary Disease - blood Coronary Disease - mortality Coronary Disease - prevention & control Coronary heart disease Databases, Factual Diabetes Mellitus - blood Diabetes Mellitus - epidemiology Female Fibrinogen - analysis General aspects Heart Humans Inflammatory diseases Interleukin-6 - blood Internal Medicine Kirurgi Kirurgisk forskning Leukocyte Count Lung Diseases - blood Lung Diseases - mortality Male Medical sciences MEDICIN MEDICINE Meta-analysis Middle Aged Mortality Motor Activity Neoplasms - blood Neoplasms - mortality Neurology Orthopaedics Ortopedi Proteins Regression Analysis Risk Assessment Risk Factors Serum Albumin Sex Factors Smoking - blood Smoking - epidemiology Statins Statistical methods Stroke - blood Stroke - mortality Stroke - prevention & control Surgery Surgical research Systematic review Triglycerides - blood Vascular diseases and vascular malformations of the nervous system
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Summary Background Associations of C-reactive protein (CRP) concentration with risk of major diseases can best be assessed by long-term prospective follow-up of large numbers of people. We assessed the associations of CRP concentration with risk of vascular and non-vascular outcomes under different circumstances. Methods We meta-analysed individual records of 160 309 people without a history of vascular disease (ie, 1·31 million person-years at risk, 27 769 fatal or non-fatal disease outcomes) from 54 long-term prospective studies. Within-study regression analyses were adjusted for within-person variation in risk factor levels. Results Loge CRP concentration was linearly associated with several conventional risk factors and inflammatory markers, and nearly log-linearly with the risk of ischaemic vascular disease and non-vascular mortality. Risk ratios (RRs) for coronary heart disease per 1-SD higher loge CRP concentration (three-fold higher) were 1·63 (95% CI 1·51–1·76) when initially adjusted for age and sex only, and 1·37 (1·27–1·48) when adjusted further for conventional risk factors; 1·44 (1·32–1·57) and 1·27 (1·15–1·40) for ischaemic stroke; 1·71 (1·53–1·91) and 1·55 (1·37–1·76) for vascular mortality; and 1·55 (1·41–1·69) and 1·54 (1·40–1·68) for non-vascular mortality. RRs were largely unchanged after exclusion of smokers or initial follow-up. After further adjustment for fibrinogen, the corresponding RRs were 1·23 (1·07–1·42) for coronary heart disease; 1·32 (1·18–1·49) for ischaemic stroke; 1·34 (1·18–1·52) for vascular mortality; and 1·34 (1·20–1·50) for non-vascular mortality. Interpretation CRP concentration has continuous associations with the risk of coronary heart disease, ischaemic stroke, vascular mortality, and death from several cancers and lung disease that are each of broadly similar size. The relevance of CRP to such a range of disorders is unclear. Associations with ischaemic vascular disease depend considerably on conventional risk factors and other markers of inflammation. Funding British Heart Foundation, UK Medical Research Council, BUPA Foundation, and GlaxoSmithKline.
ISSN:	0140-6736 1474-547X 1474-547X